Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
93 hedge funds and large institutions have $427M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2018 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 40 increasing their positions, 16 reducing their positions, and 13 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 16
102% more call options, than puts
Call options by funds: $2.05M | Put options by funds: $1.02M
82% more capital invested
Capital invested by funds: $235M → $427M (+$192M)
54% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 13
8% more funds holding
Funds holding: 86 → 93 (+7)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$11.4M |
| 2 |
BlackRock
New York
|
+$9.5M |
| 3 |
DM
Deerfield Management
New York
|
+$6.69M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.06M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$6.54M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.9M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$3.59M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$3.31M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3.12M |
RETA Hedge Fund Activity: Q2 2018 in Review
93 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q2 2018, worth a combined $427M — up 82% from $235M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new RETA positions and 13 closed out — a net gain of 7 holders — while 40 added to existing stakes and 16 trimmed.
The largest buyer was Ameriprise, adding an estimated $11.4M. The largest seller was Prosight Management, cutting an estimated $6.54M.
- 93 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q2 2018, up from 86 in Q1 2018.
- Funds reported $427M of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q2 2018, up 82% quarter-over-quarter.
- 20 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q2 2018 and 13 closed out, a net change of +7 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q2 2018 was Ameriprise, an estimated $11.4M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q2 2018 was Prosight Management, an estimated $6.54M sold.
Based on aggregated 13F filings for Q2 2018.